BREVICON 21-DAY
LOE ApproachingNDAORAL-21TABLET
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREVICON 21-DAY is an oral contraceptive tablet approved in 1974, containing a combination of hormonal agents designed to prevent pregnancy. The product is a small-molecule oral contraceptive administered on a 21-day cycle. It represents a legacy hormonal contraceptive in a market dominated by modern formulations.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) suggests declining brand team resources and focus shift toward managed care and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BREVICON 21-DAY offers limited career advancement opportunities given its LOE-approaching status and zero linked open positions. Roles focus on defensive commercial strategies, managed care negotiations, and generic transition management rather than growth initiatives.
Product ManagerBrand Manager
Worked on BREVICON 21-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.